ID | 119036 |
Author |
Bando, Hiroshi
Tokushima University|Medical Research|Integrative Medicine Japan|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
|
Keywords | sodium-glucose co-transporter-2 inhibitor (SGLT2i)
sarcopenia
visceral fat area (VFA)
skeletal muscle index (SMI)
bone mineral content (BMC)
|
Content Type |
Journal Article
|
Description | Regarding pharmacological therapy for diabetes, sodium-glucose co-transporter-2 inhibitor (SGLT2i) has been in focus for various clinical efficacy. They include cardiovascular disease, chronic heart failure (CHF) and chronic kidney disease (CKD). Various discussion has been observed concerning the relationship among diabetes, frailty, sarcopenia, SGLT2i, aging and senile syndrome. By SGLT2i, weight and visceral fat area (VFA) are decreased, and the results of skeletal muscle index (SMI) and bone mineral content (BMC) vary in some reports. Using abdominal CT, bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), muscle mass and BMC have been lately studied. SGLT2i may maintain muscle mass and function.
|
Journal Title |
International Journal of Complementary & Alternative Medicine
|
ISSN | 23811803
|
Publisher | MedCrave Publishing
|
Volume | 15
|
Issue | 4
|
Start Page | 220
|
End Page | 222
|
Published Date | 2022-07-29
|
Rights | This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
|
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|